<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580525</url>
  </required_header>
  <id_info>
    <org_study_id>2000023289</org_study_id>
    <nct_id>NCT03580525</nct_id>
  </id_info>
  <brief_title>Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol</brief_title>
  <official_title>Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled study to enroll male and female tobacco smokers menthol (n=35) and&#xD;
      non-menthol (n=35) who will participate in five experimental sessions. subjects will be given&#xD;
      an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates&#xD;
      (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight per sec).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo-controlled study that will enroll male and female tobacco smokers menthol (n=35)&#xD;
      and non-menthol (n=35) to participate in five experimental sessions. During the experimental&#xD;
      session, subjects will be given an IV infusion of either saline or 1 mg nicotine at rapid,&#xD;
      moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body&#xD;
      weight per sec). The infusion conditions for each experimental session will be determined in&#xD;
      random order. Aim 1 is to establish a dose-effect curve for positive subjective effects (drug&#xD;
      liking and good drug effects) and alleviation of smoking urges, as a function of nicotine&#xD;
      delivery rate in menthol and non-menthol cigarette preferring smokers Aim 2 is to establish a&#xD;
      dose-effect curve positive subjective effects and alleviation of smoking urges as a function&#xD;
      of nicotine delivery rate. Aim 3 is to establish a dose-effect curve for nicotine's effect to&#xD;
      alleviate symptoms of nicotine withdrawal in abstinent smokers as a function of nicotine&#xD;
      delivery rate. Aim 4 is to establish a dose-effect curve for nicotine's acute cardiovascular&#xD;
      health effects. Data from this project will help to establish benchmark values for nicotine's&#xD;
      threshold effects that will guide policies on the nicotine yield of tobacco products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single blind, placebo-controlled, mixed-design with nicotine delivery as a within-subjects factor.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will not know nicotine dose or rate of infusion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Changes on items of the Drug Effects Questionnaire (DEQ)</measure>
    <time_frame>up to 60 minutes post infusion</time_frame>
    <description>The peak change in the intensity of subjective effects as measured by the DEQ: Drug effects questionnaire; Eleven questions with a minimum score of 0 to a maximum score of 100.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>nicotine saline infusion 0.00mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.00 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.24mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.24mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.096mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.096mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.048mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.048mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.024mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.048mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine saline infusion 0.00mcg/kg/s</intervention_name>
    <description>saline 0.00mcg/kg/s</description>
    <arm_group_label>nicotine saline infusion 0.00mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.24mcg/kg/s</intervention_name>
    <description>nicotine 0.24mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.24mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.096mcg/kg/s</intervention_name>
    <description>nicotine 0.096mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.096mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.048 mcg/kg/s</intervention_name>
    <description>nicotine 0.048mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.048mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.024mcg/kg/s</intervention_name>
    <description>nicotine 0.024mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.024mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Female and male smokers, aged 18 to 35 years, who have been smoking tobacco cigarettes&#xD;
             for at least a year&#xD;
&#xD;
          -  Smoke â‰¥ 5 and less than 20 cigarettes per day;&#xD;
&#xD;
          -  Urine cotinine levels &gt; 100 ng/mL consistent with nicotine intake of an active smoker&#xD;
             (23)&#xD;
&#xD;
          -  Not seeking treatment at the time of the study for nicotine dependence;&#xD;
&#xD;
          -  In good health as verified by medical history, screening examination, and screening&#xD;
             laboratory tests&#xD;
&#xD;
          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and&#xD;
             using acceptable birth control methods.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of major medical or psychiatric disorders that the physician investigator&#xD;
             deems as contraindicated for the subject to be in the study&#xD;
&#xD;
          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or&#xD;
             anxiolytics)&#xD;
&#xD;
          -  Current alcohol or substance dependence for any other recreational or prescription&#xD;
             drugs other than nicotine&#xD;
&#xD;
          -  Use of e-cigarettes more than 10 days in the past 30 days&#xD;
&#xD;
          -  Urine drug screening indicating recent illicit drugs use (with the exception of&#xD;
             marijuana).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lance Barnes</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4823</phone_ext>
    <email>lance.barnes@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacy Minnix, B.S.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4805</phone_ext>
    <email>stacy.minnix@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Barnes</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4823</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Stacy Minnix, B.S.W.</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4805</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

